Effects of Ketones on Muscle Wasting During Caloric Restriction in Lean Females

NCT ID: NCT04744142

Last Updated: 2021-02-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-01

Study Completion Date

2019-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Because of these anabolic properties of ketone bodies and the fact that ketone bodies prevent muscle protein breakdown for gluconeogenesis during energetic stress, ketone bodies can be a promising strategy to prevent or treat skeletal muscle wasting. Therefore, our aim is to investigate the effect of 3HHB intake on muscle wasting and its adverse consequences during a period of caloric restriction in lean females. In addition, we compare the effects of 3HHB intake with a high protein diet, which is currently considered as the best strategy to minimize lean loss during hypo-energetic periods. To end, we aim to investigate the synergistic effects of the intake of 3HHB in combination with a high protein diet.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Thermodynamics state that body mass declines during periods in which energy expenditure exceeds energy intake. This negative energy balance can be obtained either by reducing energy intake, called caloric restriction, by increasing energy expenditure, i.e higher level of physical activity, or the combination of both. The sustained energy deficit results in a net loss of body weight due to losses of both fat and skeletal muscle mass in a ratio of approximately 3:11, depending on the severity of caloric restriction, diet composition and initial body fat percentage. Decreases in muscle mass are due to a combination of downregulated muscle protein synthesis in conjunction with an increased ubiquitin-proteasome-mediated muscle proteolysis, resulting in a negative net protein turnover.

In the context of sports, many athletes try to lose body weight to achieve different goals, such as improving performance by optimizing power-to-weight ratio, competing in a certain body weight category or for aesthetic reasons. However, the loss of body weight is often accompanied by detrimental loss of skeletal muscle mass, which is associated with a myriad of negative consequences including impaired physical performance and increased susceptibility to injury. Hence, athletes undergoing periods of caloric restriction strive for body weight loss via fat loss, while minimizing loss of lean mass. Recent studies have demonstrated that an increased protein intake, higher than the recommended dietary allowance (0.8g/kg/day), attenuates the loss of muscle mass during caloric restriction. Research has shown that the high protein diet has minor effects on muscle proteolysis compared to normal dietary protein but restores muscle protein synthesis, which is probably the primary mechanism by which lean mass is preserved. Specifically, in young healthy athletes, it is shown that a higher protein intake of 1.6-2.4 g per kg body weight per day reduces the loss of muscle mass during short-term caloric restriction periods.

In female athletes, longer periods of low energy availability (with or without an eating disorder) are often interrelated with menstrual dysfunctions and decreased bone mineral density, a syndrome called the 'female athlete triad'. The triad is particularly common in sports that emphasize aesthetics or leanness and can impose lifelong health consequences. However, interventions that minimize loss of lean mass and prevent hormonal and bone metabolism dysregulations in females during periods of caloric restriction, are still missing.

Ketone bodies, i.e. D-β-hydroxybutyrate (βHB), acetoacetate (AcAc) and acetone are naturally occurring chemical compounds synthesized in the liver from circulating fatty acids under conditions of low blood glucose and insulin levels. In normal physiological conditions, the concentration of serum ketone levels remains low (\< 0.1 mM). However, during starvation or applying a ketogenic diet, i.e low carbohydrate content, serum concentrations of βHB and AcAc can increase up to 5-8 mM and 1-2 mM, respectively. In these conditions, ketone bodies serve as an alternative and more efficient energy source for various tissues, including the brain, heart and skeletal muscle, thereby 'sparing' the glucose storages. In normal conditions, the brain can only use glucose as an energy fuel to maintain central nervous system functions. Therefore, sparing glucose storages during periods of energetic stress is extremely important for survival. Besides, this sparing of glucose storages prevents the breakdown of muscle proteins which can be used as precursors for gluconeogenesis, providing glucose for the brain and other tissues. Hence, the availability of ketone bodies reduces the breakdown of muscle proteins for gluconeogenesis and, thus, preserves skeletal muscle mass even when energy availability is limited. Therefore, elevating ketone body levels may be an important strategy to prevent skeletal muscle wasting during periods of energetic stress.

Since recently, serum levels of ketone bodies can be increased by the intake of the ketone body ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (3HHB). This orally absorbable ketone body ester is proven safe and well-tolerated in both animals and humans and can elevate ketone body levels within 30 min to 5-6 mM, similar to levels after approximately one week of fasting. The availability of this ketone body ester allows for controlled studies on the effect of ketone bodies on muscle homeostasis without the negative side-effects of starvation and a ketogenic diet, i.e high serum triglyceride and cholesterol levels. The effects of 3HHB on endurance performance is still debated. However, a recent study from our lab showed that post-exercise ingestion of 3HHB increases markers of protein synthesis, which was further confirmed by in vitro experiments. C2C12 myoblasts showed increased leucine-mediated muscle protein synthesis by incubation of physiological concentrations of ketone bodies. Most recently, we found that dietary supplementation with 3HHB substantially improved survival and maintenance of functional capacity and muscular integrity in a mouse model of cancer cachexia.

Because of these anabolic properties of ketone bodies and the fact that ketone bodies prevent muscle protein breakdown for gluconeogenesis during energetic stress, ketone bodies can be a promising strategy to prevent or treat skeletal muscle wasting. Therefore, our aim is to investigate the effect of 3HHB intake on muscle wasting and its adverse consequences during a period of caloric restriction in lean females. In addition, we compare the effects of 3HHB intake with a high protein diet, which is currently considered as the best strategy to minimize lean loss during hypo-energetic periods. To end, we aim to investigate the synergistic effects of the intake of 3HHB in combination with a high protein diet.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Muscle Wasting Protein Intake Ketosis Caloric Restriction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Subjects were pair-matched for body weight, % body fat and energy intake, where after they were randomly allocated to an experimental group
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Subjects were randomized by an external, independent researcher. Supplements were color and taste matched.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Received 10% protein in nutrition + placebo supplement

Group Type NO_INTERVENTION

No interventions assigned to this group

Ketone

Received 10% protein in nutrition + 3x20g B-hydroxybutyrate per day

Group Type EXPERIMENTAL

Ketone supplementation

Intervention Type DRUG

Subjects receive either placebo or ketone ester supplementation

High protein

Received 30% protein in nutrition + placebo supplement

Group Type EXPERIMENTAL

Increased protein intake

Intervention Type DIETARY_SUPPLEMENT

Subjects receive either normal or increased protein intake

High protein + ketone

Received 30% protein in nutrition + 3x20g B-hydroxybutyrate per day

Group Type EXPERIMENTAL

Ketone supplementation

Intervention Type DRUG

Subjects receive either placebo or ketone ester supplementation

Increased protein intake

Intervention Type DIETARY_SUPPLEMENT

Subjects receive either normal or increased protein intake

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ketone supplementation

Subjects receive either placebo or ketone ester supplementation

Intervention Type DRUG

Increased protein intake

Subjects receive either normal or increased protein intake

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Placebo vs ketone supplementation Normal vs increased protein intake

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Females between 18 and 40 years old
* Fat percentage between 16 and 25%
* Regularly involved in physical activity ( \> 6 h/week)
* Use of hormonal contraceptives
* Good health status confirmed by a medical screening
* Stable body weight during the last 3 months prior to the study, i.e. no changes \> 2 kg

Exclusion Criteria

* Smoking
* Obsessive pursuit for thinness, evaluated by the Eating Disorder Inventory 3 (EDI-3) 'Pursuit of leanness' (i.e a score higher than 26/32) (see Appendix 5)
* Intake of any medication or nutritional supplement that is proven to affect exercise performance, except oral contraceptives
* Blood donation during the study
* Current participation in another research trial
* Any other argument to believe that the subject is unlikely to successfully complete the full study protocol
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

KU Leuven

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Peter Hespel

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Katrien Koppo, PhD

Role: STUDY_DIRECTOR

KU Leuven

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

KU Leuven

Leuven, Vlaams-brabant, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

S61133

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.